expands and enters pipe Immunology stem cell en campo a través
Trillium Therapeutics Inc. (TTI) a biopharmaceutical company developing innovative biological immune system, has announced that it has signed two definitive licensing agreements with University Health Network (UHN) and the Hospital for Sick Children (SickKids) in Toronto, Ontario, the Trillium grant worldwide exclusive rights to commercialize two programs in the areas of immunology transplantation hematopoietic stem cells and cancer.
"We are very pleased to have strengthened our franchise in immunology and have strengthened our existing ties with the world of Toronto community of immunology class. Our relationship with long-term productive UHN is a good omen for the success of this new collaboration, "said Dr. Niclas Stiernholm, CEO of Trillium. "This transaction is an example of how Canadian soil science deals can and should be marketed by our national biotechnology industry, something that should be encouraged and supported also by the government and investor groups.
The first project approved by TTI is to improve the engraftment of hematopoietic stem cells by way of a key immunoregulatory anxious to evade the host immune system from attacking the transplanted stem cells. The second program focuses on the treatment of various cancers by way of antagonizing the same cancer stem cells, stimulating the patient's own immune system to attack cancer. Drs. John Dick, and Jean Wang of UHN, and Dr. Jayne Danish, world renowned scientists in their respective fields and the inventors of these technologies, first published its initial findings in the journal Nature Immunology in December 2007. Through co-sponsored research agreements, which will work closely with Trillium scientific team to advance this cutting-edge science of human testing.
Dr. Christopher Paige, VP Research at UHN said: "We are very pleased to have established this partnership with a dynamic company like Canadian biotechnology Trillium Therapeutics. Represents an excellent example of how research in hospitals and SickKids can work UHN together to translate cutting-edge discoveries research on new product development opportunities. "Dr. Janet Rossant, SickKids Chief of Research added" research collaborations between scientists of our institutions have now been extended to interactions with the private sector development, which clearly indicates that we can provide research and biotherapeutic development together in Toronto. "
Related article
cord
Bank
cord stem cell bank
umbilical cord stem cells
0 comments:
Post a Comment